NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis $0.73 +0.08 (+12.31%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.71 -0.02 (-3.01%) As of 07/11/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Windtree Therapeutics Stock (NASDAQ:WINT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Windtree Therapeutics alerts:Sign Up Key Stats Today's Range$0.65▼$0.7550-Day Range$0.37▼$1.0252-Week Range$0.36▼$737.44Volume2.22 million shsAverage Volume2.04 million shsMarket Capitalization$2.67 millionP/E RatioN/ADividend YieldN/APrice Target$350.00Consensus RatingHold Company Overview Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular and pulmonary diseases. The company’s proprietary technology platforms include the KL4 surfactant formulation and the Aerosurf® (formerly AeriSeal®) polymer foam technology, both designed to address critical conditions such as neonatal respiratory distress syndrome (nRDS), acute respiratory distress syndrome (ARDS), and alveolar leaks associated with mechanical ventilation. By combining expertise in lipid science, pulmonary delivery, and critical care medicine, Windtree aims to fill unmet medical needs across a range of acute and life-threatening indications. Windtree’s product pipeline is anchored by its lead asset, KL4 surfactant, which is being evaluated for the prevention and treatment of nRDS in premature infants and for inflammatory lung diseases in adults. The Aerosurf polymer foam technology is engineered to seal alveolar air leaks and has potential applications in critical care settings, including ARDS and bronchopleural fistulas. In addition to these core programs, the company has initiated exploratory studies for potential treatments of pulmonary alveolar proteinosis and other rare lung disorders. Since its founding in 2006 and subsequent public listing on the NASDAQ under the ticker WINT, Windtree has maintained headquarters in Warrington, Pennsylvania, with research collaborations and clinical trial sites across North America, Europe, and Asia. The company leverages strategic partnerships with academic institutions, contract research organizations, and healthcare providers to support its global clinical development activities. Windtree’s management team brings together seasoned professionals from the pharmaceutical and biotechnology sectors. The company is led by Chief Executive Officer Robert Pangia, whose prior roles include senior leadership positions at specialty pharma and medical device companies. The board of directors comprises independent members with deep expertise in drug development, regulatory affairs, and commercial strategy. Together, Windtree’s leadership is committed to advancing its portfolio through late-stage clinical trials and toward potential regulatory approvals. AI Generated. May Contain Errors. Read More Windtree Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreWINT MarketRank™: Windtree Therapeutics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingWindtree Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWindtree Therapeutics has received no research coverage in the past 90 days.Read more about Windtree Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Windtree Therapeutics are expected to grow in the coming year, from ($5.66) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Windtree Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Windtree Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWindtree Therapeutics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Windtree Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.43% of the float of Windtree Therapeutics has been sold short.Short Interest Ratio / Days to CoverWindtree Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Windtree Therapeutics has recently decreased by 82.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWindtree Therapeutics does not currently pay a dividend.Dividend GrowthWindtree Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.43% of the float of Windtree Therapeutics has been sold short.Short Interest Ratio / Days to CoverWindtree Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Windtree Therapeutics has recently decreased by 82.63%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News SentimentN/A News SentimentWindtree Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Windtree Therapeutics this week, compared to 2 articles on an average week.Search Interest19 people have searched for WINT on MarketBeat in the last 30 days. This is an increase of 1,800% compared to the previous 30 days.MarketBeat Follows2 people have added Windtree Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.33% of the stock of Windtree Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.33% of the stock of Windtree Therapeutics is held by institutions.Read more about Windtree Therapeutics' insider trading history. Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address WINT Stock News HeadlinesWindtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - NasdaqJuly 4, 2025 | nasdaq.comWindtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart FailureJuly 2, 2025 | globenewswire.comAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.July 12 at 2:00 AM | Paradigm Press (Ad)Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim AnalysisJune 30, 2025 | finance.yahoo.comWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelJune 26, 2025 | globenewswire.comWindtree Therapeutics Announces Promising Phase 2 Study Results for IstaroximeJune 17, 2025 | msn.comWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14, 2025 | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deSee More Headlines WINT Stock Analysis - Frequently Asked Questions How have WINT shares performed this year? Windtree Therapeutics' stock was trading at $17.4650 at the beginning of 2025. Since then, WINT shares have decreased by 95.8% and is now trading at $0.73. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) released its quarterly earnings data on Thursday, May, 15th. The company reported ($4.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($39.00) by $34.37. When did Windtree Therapeutics' stock split? Windtree Therapeutics's stock reverse split before market open on Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Windtree Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings5/15/2025Today7/12/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WINT CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees30Year FoundedN/APrice Target and Rating Average Price Target for Windtree Therapeutics$350.00 High Price Target$350.00 Low Price Target$350.00 Potential Upside/Downside+47,845.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($823.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-227.93% Return on Assets-56.46% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$38.99 per share Price / Book0.02Miscellaneous Outstanding Shares3,660,000Free Float3,649,000Market Cap$2.67 million OptionableNot Optionable Beta0.70 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:WINT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.